Double immunotherapy attack after Chemo-Radiation shows promise for lung cancer
NCT ID NCT03285321
First seen Jan 24, 2026 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) after standard chemoradiation could better control stage III lung cancer compared to nivolumab alone. 105 patients were randomly assigned to one of the two treatment groups. The main goal was to see how long patients lived without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins Sidney Kimmel Comprehensive
Baltimore, Maryland, 21287, United States
-
Karmanos Cancer Center (Wayne State University)
Detroit, Michigan, 48201, United States
-
Michigan State University
Lansing, Michigan, 48910, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky, 40202, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo) and ipilimumab (Yervoy)
What this could lead to
If successful, this could offer a more effective way to keep stage III lung cancer from progressing after standard chemoradiation, potentially extending the time before the disease worsens.
What could go wrong
This is a relatively small Phase 2 trial, so results may not be definitive. Combining two immunotherapy drugs can increase the risk of serious immune-related side effects, and the benefit over standard care is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.